A Randomized Dose-Finding Study of Anti-KIT Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Allergic Diseases

Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria

J Eur Acad Dermatol Venereol

Zhang DG, Nielsen ML, Sørensen JA, Naassan S, Vestergaard C, Kocatürk E, Ali Z, Thyssen JP, Egeberg A, Thomsen SF

doi: 10.1111/jdv.20737

Autoimmune Disease

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials

JAMA Dermatol

Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M

doi: 10.1001/jamadermatol.2025.6023

Atopic Dermatitis

Remibrutinib in chronic spontaneous urticaria: 52-Week results from two phase 3 studies

J Allergy Clin Immunol

Giménez-Arnau AM, Szalewski R, Hide M, Jain V, Khemis A, Lebwohl M, Metz M, Mosnaim G, Palumbo M, Şavk E, Sussman G, Walecka-Herniczek I, Yang B, Field C, Haemmerle S, Lheritier K, Machado PGP, Martzloff ED, Seko N, Wang P, Zharkov A, Saini S

doi: 10.1016/j.jaci.2025.09.028

Further Publications Dermatology

Family quality-of-life burden in chronic spontaneous urticaria: A multicentre study

J Eur Acad Dermatol Venereol

Abdalla BMZ, Criado RFJ, Kulthanan K, Kocatürk E, Cherrez-Ojeda I, Giménez-Arnau AM, Maurer M, Ensina LF, Bernstein JA, Hide M, Dortas Junior SD, Valle SOR, Gabriela D, Xepapadak P, Priyanshi D, Podder I, Trajkova V, Teovska Mitrevska N, Iman HN, Bushra AH, Bartosińska J, Krasowska D, Paulina SK, Hilal G, Ozceker D, Çiçek K, Özkaya E, Erdem Y, Ergün M, Tosun M, Kara RO, Li J, Allenova A, Criado PR

doi: 10.1111/jdv.70290

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Immunodeficiency

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

J Clin Immunol

Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J

doi: 10.1007/s10875-025-01952-5

Vitiligo

Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study

J Am Acad Dermatol

Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos LL, Erskine L, Wagya K, Blauvelt A

doi: 10.1016/j.jaad.2025.06.027

Allergic Diseases

Omalizumab in pediatric chronic spontaneous urticaria: A systematic review and meta-analysis of efficacy and safety

Pediatr Allergy Immunol

Alomari O, Ozceker D, Mokresh ME, Topçak AB, Ertan SN, Şahin MK, Çalışkan N, Karadag SIK, Erbay MF, Yıldırım G, Bologur H, Güngör H, Kaplan O, Tunç HS, Göncü EK

doi: 10.1111/pai.70132

Related content